SEATTLE, November 24, 2025 — Leads & Copy — Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced its clonoSEQ® test for measurable residual disease (MRD) assessment will be highlighted in 89 abstracts, with 36 oral presentations, at the American Society of Hematology (ASH) Annual Meeting, Dec. 6–9, in Orlando.
Key highlights from the ASH presentations include:
Abstracts featuring clonoSEQ MRD data span multiple myeloma (MM), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and other blood cancers. These presentations underscore clonoSEQ’s position as a widely used and validated next-generation sequencing-based MRD test in lymphoid malignancies.
Over 17 presentations demonstrate how clonoSEQ MRD assessment is informing patient treatment decisions in real-world clinical practice, including studies to guide treatment in ALL, CLL, MM, MCL and DLBCL.
The continued expansion of clonoSEQ use in clinical trials is enabling the deepest assessment of treatment responses for novel regimens and across a wide range of therapeutic modalities, including CAR T, bispecific antibodies, and other targeted therapies.
Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies, said the breadth of ASH presentations incorporating clonoSEQ this year highlights how integral MRD testing has become in patient care and clinical research across hematologic oncology. She added that the momentum reflects the multifaceted role MRD is playing in modern lymphoid cancer care, from guiding treatment decisions to accelerating therapeutic innovation.
clonoSEQ® is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL.
The clonoSEQ test identifies and quantifies DNA sequences in malignant cells, detecting one cancer cell in one million healthy cells, to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier.
clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request. To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. The company’s proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed.
Adaptive Biotechnologies partners with biopharmaceutical companies, informs drug development, and develops clinical diagnostics across two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Its commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. The company’s goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Adaptive Investors Contact:
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com
Adaptive Media Contact:
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com
Source: Adaptive Biotechnologies Corporation
